Vidaza (Azacitidine 100 MG/Vial)
Vidaza (Azacitidine)
- Medicine Name: Vidaza
- API: Azacitidine
- Dosage Form & Strength: Injection: lyophilized powder in 100 mg single-dose vials
- Manufactured By: Celgene Corporation
- Adult patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).
- Pediatric patients aged 1 month and older with newly diagnosed Juvenile Myelomonocytic Leukemia (JMML).
- Patients should be treated for a minimum of 3 cycles and maximum of 6 cycles.
- for patients aged 1 month to less than 1 year or weighing less than 10 kg: The recommended dose is 2.5 mg/kg.
- for patients aged 1 year and older and weighing 10 kg or greater: The recommended dose is 75 mg/m2.
- Azacitidine 100 mg injection can cause severe bone marrow suppression, leading to reduced levels of white blood cells, red blood cells, and platelets. This increases the risk of infections, anemia, and bleeding. Regular blood tests are necessary to monitor blood cell counts, and dose adjustments or treatment interruptions may be required based on the results.
- Due to bone marrow suppression, patients are at a higher risk of infections. Symptoms such as fever, chills, or signs of localized infections should be reported immediately. Preventive measures, such as good hygiene and avoiding exposure to sick individuals, are crucial.
- Treatment with Azacitidine can cause renal toxicity, leading to an increase in serum creatinine and other markers of kidney function. Regular monitoring of renal function is recommended, and patients should stay well-hydrated. Any signs of renal impairment should prompt immediate medical evaluation.
- This medicinal product can also affect liver function, causing elevated liver enzymes and bilirubin levels. Liver function tests should be conducted regularly. Patients should report symptoms like jaundice, dark urine, or upper abdominal pain.
- Azacitidine injection may cause TLS, a rapid release of cancer cell contents into the bloodstream, which can lead to serious metabolic disturbances. Patients at high risk should be monitored closely, and preventive measures, such as hydration and medications, may be necessary.
- Cardiac and pulmonary toxicity, including congestive heart failure and pulmonary fibrosis, have been reported. Patients should be monitored for symptoms like chest pain, shortness of breath, or persistent cough, and any issues should be promptly addressed.
- The medicine Azacitidine can cause fetal harm when administered to pregnant women and should be avoided during pregnancy. Effective contraception should be used during treatment. It is unknown if it is excreted in human milk; breastfeeding should be stopped during treatment.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patient ID proof (issued by the government of India)
- A valid prescription from the Doctor
- Import permit if applicable
- On availability of Vidaza in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
- Medicine Price.
- Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
- Ensuring 100% transparency.
Indian Pharma Network can source the VIDAZA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Vidaza®?
Azacitidine is a Generic Name for the trade name drug Vidaza®.
What is the Manufacturer’s Name of Vidaza®?
Vidaza® is manufactured by Celgene Corporation.
Is Vidaza® approved by the FDA?
Yes, Vidaza® is approved by the FDA. Date of first approval: May 19, 2004.
What is the dosage and form of Vidaza® supplied?
Vidaza® is supplied as a lyophilized powder in 100 mg single-dose vials for subcutaneous or intravenous use.
What are the most common side effects of Vidaza®?
The most common side effects of Vidaza® in adult patients with MDS by the subcutaneous (SC) route are thrombocytopenia, vomiting, nausea, anemia, pyrexia, leukopenia, injection site erythema, constipation, diarrhea, neutropenia, and ecchymosis. The most common side effects by intravenous (IV) route also included weakness, petechiae, rigors, and hypokalemia.
The most common side effects by intravenous route in pediatric patients with JMML are pyrexia, rash, anemia, and upper respiratory tract infection.
How much does Vidaza® cost in India?
Prices may fluctuate over time due to market dynamics and regulatory changes. To obtain accurate and up-to-date information on the cost of Vidaza in India, it is recommended to Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Vidaza®?
Vidaza® (azacitidine) should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect it from light, and do not freeze. Store in the original container.
Is it safe to buy Vidaza® online in India?
Yes, one can buy Vidaza online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in the country. We can help facilitate the supply of Vidaza® through legal channels.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.